REG - BiVictriX Therapcts. - BiVictriX Director Dealing

Bivictrix TherapeuticsAnnouncement

09/03/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220309:nRSI1106Ea&default-theme=true

RNS Number : 1106E  BiVictriX Therapeutics PLC  09 March 2022

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK
VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH
LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

9 March 2022

 

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or "the Company")

 

Director Dealing

 

Alderley Park, 9 March 2022 BiVictriX Therapeutics plc (AIM: BVX), an
emerging biotechnology company applying a novel approach to develop next
generation cancer therapies using insights derived from frontline clinical
experience, today announces the following dealing in the Company's ordinary
shares of 1 pence each ("Ordinary Shares").

 

On 8 March 2022, 100,000 Ordinary Shares at a price of 22.25 pence each were
purchased by Iain Ross, Chairman of the Company, through his self-invested
personal pension (SIPP).

Following this purchase, Mr Ross is benefically interested in 400,000 Ordinary
Shares representing 0.61 per cent of the Company's total issued share capital.

 

-Ends-

 

 

 For more information, please contact:

BiVictriX Therapeutics plc
 Tiffany Thorn, Chief Executive Officer               Email: info@bivictrix.com

 Iain Ross, Chairman
                                                     Tel: +44 (0) 20 3470 0470

 SP Angel Corporate Finance LLP (NOMAD and Broker)
 David Hignell, Caroline Rowe (Corporate Finance)

 Vadim Alexandre, Rob Rees (Sales and Broking)

 Panmure Gordon (UK) Limited (Joint Broker)          Tel: +44 (0) 20 7886 2500
 Rupert Dearden/Freddy Crossley/Emma Earl

 Consilium Strategic Communications
 Mary-Jane Elliott, Genevieve Wilson, Alex Gunter    Tel: +44 (0) 20 3709 5700

                           Email: Bivictrix@consilium-comms.com

 

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is
focused on leveraging clinical experience to develop a class of highly
selective, next generation cancer therapeutics which exhibit superior potency,
whilst eliminating treatment-related toxicities.

 

The Company utilises a first-in-class approach to generate a proprietary
pipeline of Bi-Cygni® therapeutics which are designed to selectively target
antigen co-expression fingerprints, or "twin antigens", on tumour cells, which
are largely absent from healthy cells. Whereas this concept has been validated
in a clinical diagnostic setting to support the diagnosis and monitoring of
haematological cancers, it has not yet been widely used in a therapeutic
setting.

 

BiVictriX has identified a diverse panel of novel cancer-specific "twin
antigens", across a broad range of cancer indications including Diffuse Large
B Cell Lymphoma, Acute Myeloid Leukaemia and Blastic Plasmacytoid Dendritic
Cell Neoplasm. The Company is using these novel "twin-antigens" to develop
more effective and safer therapeutics to target cancers that are expected to
constitute orphan indications and currently constitute areas of high unmet
medical need.

 

Find out more about BiVictriX online at www.bivictrix.com
(http://www.bivictrix.com)

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them.

 

 1.    Details of the person discharging managerial responsibilities / person closely
       associated
 a)    Name                                                         Iain Ross

 2.    Reason for the Notification
 a)    Position/status                                              Non-Executive Chairman
 b)    Initial notification/Amendment                               Initial notification
 3.    Details of the issuer, emission allowance market participant, auction
       platform, auctioneer or auction monitor
 a)    Name                                                         BiVictriX Therapeutics plc
 b)    LEI                                                          213800ZI85IZNA6N3L53
 4.    Details of the transaction(s): section to be repeated for (i) each type of
       instrument; (ii) each type of transaction; (iii) each date; and (iv) each
       place where transactions have been conducted
 a)    Description of the Financial instrument, type of instrument  Ordinary Shares of 1 pence each

                                                                    GB00BNXH3K91
       Identification code
 b)    Nature of the transaction                                    Purchase of Ordinary Shares via SIPP
 c)    Price(s) and volume(s)

Price(s)  Volume(s)
                                                                    22.25 p   100,000
 d)    Aggregated information:                                      Price(s)  Volume(s)

                                                            22.25p    100,000
       -  Aggregated volume

       -  Price
 e)    Date of the transaction                                      8 March 2022
 f)    Place of the transaction                                     AIM, London Stock Exchange

d)

Aggregated information:

-  Aggregated volume

-  Price

 Price(s)  Volume(s)
 22.25p    100,000

e)

Date of the transaction

8 March 2022

f)

Place of the transaction

AIM, London Stock Exchange

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHDDGDXCBGDGDI